Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07441642) titled 'A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration' on Feb. 24.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Geographic Atrophy Secondary to Age-related Macular Degeneration
Intervention:
Drug: FWY003
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: March 9, 2026
Target Sample Size: 272
...